“We are pleased with the strong interest from clinical investigators, clinical trial sites, and study participants in our Phase 3 SELVA study which together has led to exceeding our Phase 3 enrollment target of 40 patients,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. “Based on a recently presented epidemiology study estimating diagnosed U.S. prevalence and incidence of lymphatic malformations with cutaneous involvement, the data continue to support a large potential market opportunity for QTORIN(TM) rapamycin, if approved, as potentially the first targeted therapy for this serious, rare genetic disease which currently has no FDA-approved therapies.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Promising Potential of QTORIN in Addressing Unmet Needs in Vascular Anomalies: A Buy Recommendation for Palvella Therapeutics
- Palvella Therapeutics granted U.S patent for QTORIN Rapamycin
- Palvella Therapeutics announces data on QTORIN rapamycin
- Palvella Therapeutics initiated with a Buy at Chardan
- Palvella Therapeutics price target raised to $53 from $39 at Canaccord